Navigation Links
Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss
Date:8/11/2009

o be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and products liability claims. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development.

In addition, sales of our products are affected by the reimbursement policies imposed by third-party payors, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products. In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products. We believe that some of our newer products, product candidates or new indications for existing products, may face competition when and as they are approved and marketed. Our products may compete against products that have lower prices, established reimbursement, superior performance, are easier to administer, or that are otherwise competitive with our products. In addition, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors and there can be no guarantee of our ability to obtain or maintain patent protection for our products or produc
'/>"/>

SOURCE Amgen Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
2. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
3. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
4. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
5. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes
8. Isis Announces $1.2 Million Award to Its Ibis Subsidiary to Expand Influenza Detection Capabilities and Enable Large-Scale Influenza Transmission Studies
9. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
10. Studies Show Body Mass Index Has No Effect on Resolution and Healing of GERD Symptoms
11. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  In an unprecedented effort to curb the ... ambulances and other transport vehicles, an advanced and portable UV germicidal ... for the first time. In order to prevent ... deadly pathogens, West Palm Beach Fire Rescue ...
(Date:1/15/2014)...  According to Millennium Research Group (MRG), the global ... the United States and European transcatheter ... moderately through 2022, with embolization particles representing one ... in drug-eluting beads (DEBs) and radioembolization spheres in ...
(Date:1/15/2014)... NEW YORK , Jan. 15, ... new market research report is available ... Global Markets and Technologies for ... on Routes of Administration ...
Breaking Medicine Technology:Superbugs No Longer Ride In Rescue Vehicles 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16
... March 23, 2011 Available at ... this patent portfolio discloses methods and techniques related to ...   http://photos.prnewswire.com/prnh/20100614/CG20517LOGO ) Background ... has inherent problems. Orally administered drugs (e.g., tablets or ...
... March 23, 2011 In a letter ... Federal Trade Commission (FTC) warns that a bill shifting ... Mississippi Insurance Commissioner to the Board of Pharmacy "may ... states that the Mississippi legislature should "seriously consider whether ...
Cached Medicine Technology:ICAP Ocean Tomo Announces Auction of Patch Based Drug Delivery and Monitoring Techniques from Entrega Laboratories, LLC 2ICAP Ocean Tomo Announces Auction of Patch Based Drug Delivery and Monitoring Techniques from Entrega Laboratories, LLC 3Federal Trade Commission: Mississippi SB 2445 'Likely Will Increase Drug Costs, Reduce Competition' 2
(Date:7/9/2014)... in almost all types of cancer sends the protein ... fuel a tumour,s uncontrolled growth, new research suggests. , ... a molecular trigger responsible for ratcheting up activity of ... makes the building blocks cancer cells need to keep ... called SREBP, controls the flow of messages to the ...
(Date:7/9/2014)... found that fecal transplantation is effective and safe for ... is the result of a study led by Colleen ... Gastrointestinal Medicine at The Women,s Medicine Collaborative. The study ... of print in the American Journal of Gastroenterology ... diff , has increased to epidemic proportions over the ...
(Date:7/9/2014)... There has been a sharp increase in the number ... MyChart, the online, interactive service that allows patients to ... providers, schedule appointments, and renew prescriptions. , Over a ... MyChart each year increased five-fold, while the number ... according to a study by Dr. David Gerber ...
(Date:7/9/2014)... Allergy and Infectious Diseases (NIAID), part of the ... clinical trial of CRS3123, an investigational oral antibiotic ... C. difficile ) infection. CRS3123 (previously known as ... difficile growth while sparing normal intestinal bacteria. , ... 30 healthy men and women ages 18 to ...
(Date:7/9/2014)... , , , , , , ... , , , , , ... a binaural recording using KEMAR, the weapon was an SA80 assault rifle and the microphone is 50m downrange from the firer and approximately 30cm from the ... , , , , ... , , , , , ...
Breaking Medicine News(10 mins):Health News:Signal may send cancer's cellular factories into overdrive 2Health News:Women's Medicine Collaborative examines safety of fecal transplant to treat C. difficile 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 3Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 4Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 5Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 6Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 7
... 2008 -- In the December issue of ... Nickel and associates report on the evidence of ... tract symptoms (LUTS) in men enrolled in the ... of prostate Cancer Events) trial is a 4-year, ...
... Northridge Hospital Medical,Center (Northridge) credits TeleHealth Services, ... the organization,s recent awards and top,accreditation, all ... comfort as its medical experts provide superior ... acute care facility located in Northridge, CA,Northridge ...
... Indication for Bothersome Vaginal Symptom Associated,With Menopause, ... Cream 0.5 g has been approved by the ... indication and a new less,frequent twice-weekly dosing regimen ... intercourse) announced Wyeth,Pharmaceuticals, a division of Wyeth (NYSE: ...
... traditional chemotherapy agents with targeted therapies called monoclonal ... in patients with advanced non-small cell lung cancer ... Chicago Multidisciplinary Symposium in Thoracic Oncology, sponsored by ... The combination of bevacizumab and chemotherapy has been ...
... A new research study underway at Cardiff University ... treatment failure among patients with end-stage kidney disease. ... Inflammation Interdisciplinary Research Group at the School of ... the ,Renal Discoveries - The Baxter Extramural Grant, ...
... one of those shoppers who,wake up at 4am on Black ... "It is important not to disturb your circadian rhythm ... SSA. "The body,operates better on a good night,s sleep which ... of dawn the day after Thanksgiving.", SSA retailers nationwide ...
Cached Medicine News:Health News:Relationship between prostate information and lower urinary-tract symptoms evident 2Health News:TeleHealth Services' TIGR(R) Interactive Patient Education System Facilitates Award-Winning Results at Northridge Hospital Medical Center 2Health News:TeleHealth Services' TIGR(R) Interactive Patient Education System Facilitates Award-Winning Results at Northridge Hospital Medical Center 3Health News:FDA Approves Low-dose Regimen of PREMARIN Vaginal Cream to Treat Moderate to Severe Postmenopausal Dyspareunia - Painful Sexual Intercourse 2Health News:FDA Approves Low-dose Regimen of PREMARIN Vaginal Cream to Treat Moderate to Severe Postmenopausal Dyspareunia - Painful Sexual Intercourse 3Health News:FDA Approves Low-dose Regimen of PREMARIN Vaginal Cream to Treat Moderate to Severe Postmenopausal Dyspareunia - Painful Sexual Intercourse 4Health News:Chemotherapy plus targeted therapies shows improved survival in advance-stage lung cancer patients 2Health News:Cardiff scientists study acute infection in end-stage kidney disease patients 2Health News:Don't Disturb Your Circadian Rhythm This Black Friday 'Sleep In, Nap Later,' says Specialty Sleep Association 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: